FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4212806812> ?p ?o ?g. }

• W4212806812 endingPage "259" @default.
• W4212806812 startingPage "259" @default.
• W4212806812 abstract "259 Background: A number of reports have been published on both moderately hypofractionated intensity-modulated radiation therapy (IMRT) for localized prostate cancers using 2.4 – 3.4 Gy per fraction over 4 – 6 weeks, and ultrahypofractionation over 1 – 2 weeks using 6 Gy or more per fraction. However, long-term outcomes have sparsely been reported using doses between these two fractionations (3.4 – 6.0 Gy per fraction) over 2 – 3 weeks (high hypofractionation). Therefore, we performed a pilot study of highly hypofractionated IMRT in 15 fractions using 3.6 Gy per fraction over 3 weeks for localized prostate cancer. We now report the long-term outcomes of the study. Methods: Twenty-five patients with low- to intermediate-risk prostate cancer were enrolled in this prospective study from April 2014 to September 2015. Fifty-four Gy in 15 fractions (3.6 Gy per fraction) was delivered over three weeks using IMRT with CBCT-based image guidance without intraprostatic fiducial markers. Based on an estimated alpha/beta ratio for prostate cancer of 1.5 Gy, the EQD2 was 78.7 Gy for the present dose fractionation. Neoadjuvant hormonal therapy (HT) was administered to intermediate-risk patients for 4 – 8 months, but was not mandatory in patients with low-risk disease. Adjuvant HT was not provided for any patient. Biochemical relapse-free survival (BRFS), clinical relapse-free survival (CRFS), overall survival (OS), and the cumulative incidence rate of late toxicities were analyzed using the Kaplan Meier method. Results: Twenty-four patients were treated with highly hypofractionated IMRT, except one case switched to conventionally fractionated IMRT because we could not meet the dose constraint of the small bowel in treatment planning. Among the 24 patients, 17 % had low-risk, and 83% had intermediate-risk disease. Neoadjuvant HT was administered to 23 patients, and the median duration of HT was 5.3 months. The median follow-up period was 77 months (range, 57–87 months). BRFS, CRFS, and OS were 91.7%, 95.8% and 95.8% at 5 years, and 87.5%, 86.3% and 95.8% at 7 years, respectively. No patient died of prostate cancer, but one patient died due to the other cancer. Neither grade ≥2 late gastrointestinal toxicity nor ≥3 late genitourinary toxicity was observed. Grade 2 late genitourinary toxicity did not occur during the first 4 years, but was developed in 5 patients after more than 4-year follow-up. The cumulative incidence rate was 12.9% and 22.8% at 5 and 7 years, respectively. Conclusions: Highly hypofractionated IMRT delivering 54 Gy in 15 fractions over 3 weeks for prostate cancer without intraprostatic fiducial markers demonstrates favorable oncological outcomes with no severe complications. This treatment approach could be a possible alternative of moderate hypofractionation, although further studies will be mandatory." @default.
• W4212806812 created "2022-02-24" @default.
• W4212806812 creator A5000762247 @default.
• W4212806812 creator A5007998286 @default.
• W4212806812 creator A5017837466 @default.
• W4212806812 creator A5023608537 @default.
• W4212806812 creator A5035644148 @default.
• W4212806812 creator A5045706772 @default.
• W4212806812 creator A5081152216 @default.
• W4212806812 date "2022-02-20" @default.
• W4212806812 modified "2023-09-30" @default.
• W4212806812 title "Long-term outcomes of a pilot study on highly hypofractionated intensity-modulated radiation therapy over three weeks for localized prostate cancer." @default.
• W4212806812 doi "https://doi.org/10.1200/jco.2022.40.6_suppl.259" @default.
• W4212806812 hasPublicationYear "2022" @default.
• W4212806812 type Work @default.
• W4212806812 citedByCount "0" @default.
• W4212806812 crossrefType "journal-article" @default.
• W4212806812 hasAuthorship W4212806812A5000762247 @default.
• W4212806812 hasAuthorship W4212806812A5007998286 @default.
• W4212806812 hasAuthorship W4212806812A5017837466 @default.
• W4212806812 hasAuthorship W4212806812A5023608537 @default.
• W4212806812 hasAuthorship W4212806812A5035644148 @default.
• W4212806812 hasAuthorship W4212806812A5045706772 @default.
• W4212806812 hasAuthorship W4212806812A5081152216 @default.
• W4212806812 hasConcept C121608353 @default.
• W4212806812 hasConcept C126322002 @default.
• W4212806812 hasConcept C126894567 @default.
• W4212806812 hasConcept C143998085 @default.
• W4212806812 hasConcept C155806632 @default.
• W4212806812 hasConcept C188816634 @default.
• W4212806812 hasConcept C2776235491 @default.
• W4212806812 hasConcept C2778311097 @default.
• W4212806812 hasConcept C2780192828 @default.
• W4212806812 hasConcept C2989005 @default.
• W4212806812 hasConcept C509974204 @default.
• W4212806812 hasConcept C71924100 @default.
• W4212806812 hasConcept C72563966 @default.
• W4212806812 hasConcept C88879693 @default.
• W4212806812 hasConceptScore W4212806812C121608353 @default.
• W4212806812 hasConceptScore W4212806812C126322002 @default.
• W4212806812 hasConceptScore W4212806812C126894567 @default.
• W4212806812 hasConceptScore W4212806812C143998085 @default.
• W4212806812 hasConceptScore W4212806812C155806632 @default.
• W4212806812 hasConceptScore W4212806812C188816634 @default.
• W4212806812 hasConceptScore W4212806812C2776235491 @default.
• W4212806812 hasConceptScore W4212806812C2778311097 @default.
• W4212806812 hasConceptScore W4212806812C2780192828 @default.
• W4212806812 hasConceptScore W4212806812C2989005 @default.
• W4212806812 hasConceptScore W4212806812C509974204 @default.
• W4212806812 hasConceptScore W4212806812C71924100 @default.
• W4212806812 hasConceptScore W4212806812C72563966 @default.
• W4212806812 hasConceptScore W4212806812C88879693 @default.
• W4212806812 hasIssue "6_suppl" @default.
• W4212806812 hasLocation W42128068121 @default.
• W4212806812 hasOpenAccess W4212806812 @default.
• W4212806812 hasPrimaryLocation W42128068121 @default.
• W4212806812 hasRelatedWork W1980245127 @default.
• W4212806812 hasRelatedWork W2034738338 @default.
• W4212806812 hasRelatedWork W2092577047 @default.
• W4212806812 hasRelatedWork W2098154216 @default.
• W4212806812 hasRelatedWork W2106003470 @default.
• W4212806812 hasRelatedWork W2127440557 @default.
• W4212806812 hasRelatedWork W2321033326 @default.
• W4212806812 hasRelatedWork W2897445903 @default.
• W4212806812 hasRelatedWork W3029905168 @default.
• W4212806812 hasRelatedWork W83392053 @default.
• W4212806812 hasVolume "40" @default.
• W4212806812 isParatext "false" @default.
• W4212806812 isRetracted "false" @default.
• W4212806812 workType "article" @default.